Evolution of Diabetes Insulin Delivery Devices
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The first manufactured insulin pump was introduced in the 1970s and the first insulin pens in 1985; since then, many improvements have been made to both devices. The advantages of pens over syringes have been confirmed in numerous studies and include greater accuracy, ease of use, patient satisfaction, quality of life, and adherence. United States claims database analyses indicate that the improved adherence made possible by use of an insulin pen has the potential to reduce diabetes care costs when compared with using a vial and syringe. Features of certain advanced pump models include the ability to connect wirelessly to a blood glucose meter or to a subcutaneous interstitial glucose sensor for semicontinuous glucose-driven insulin rate adjustment. A new trend in the design of insulin pumps is the tubing-free patch pump that adheres directly to the skin. The low rate of insulin pen usage in the United States compared with European countries and the fact that many patients report that they are not offered the option of an insulin pen by their physician suggest that there is a need to increase patient and provider awareness of the currently available devices for insulin administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes
Plotnick, L. P., Clark, L. M., Brancati, F. L., & Erlinger, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1142 · Cited by 216
Dermatological Complications of Continuous Subcutaneous Insulin Infusion in Children and Adolescents
Conwell, L. S., Pope, E., Artiles, A. M., Mohanta, A., Daneman, A., & Daneman, D. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.10.006 · Cited by 111
Cited by
Insulin delivery methods: Past, present and future
Shah, R., Shah, V., Patel, M., & Maahs, D. (2016) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.176456 · Cited by 287
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
“Insulin pens offer benefits to patients, including more accurate dosing, ease of use, more social acceptability, and less time to prepare and administer injections (99).”
BackgroundSubcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138
Berg, A. K., Nørgaard, K., Thyssen, J. P., Zachariae, C., Hommel, E., Rytter, K., & Svensson, J. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0088 · Cited by 87
“5,16,17 The development of closed-loop artificial pancreas systems to treat patients with T1D provides hope that in the near future, these systems may improve metabolic control andresultin less blood glucose variability.”
Lasalvia, P., Barahona-Correa, J. E., Romero-Alvernia, D. M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J. G., Triana, J. J., Laserna, A. F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633721 · Cited by 63
“Pen devices have attained a wide diffusion,(1) despite limited evidence comparing their effectiveness against the traditional vial and syringe (VaS).(2) Our aim was to perform a systematic review of literature on the effectiveness and safety profiles of these 2 options for insulin administration.”
Background
Metadata
- Authors
- Selam, J.-L.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2010-05
- Volume
- 4
- Issue
- 3
- Pages
- 505-513
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2154310398
- Cited by
- 116
- References
- 2
- Type
- conference abstract
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution of Diabetes Insulin Delivery Devices. https://app.cochat.ai/papers/10.1177/193229681000400302
- The paper
- Selam, J.-L. (2010). Evolution of Diabetes Insulin Delivery Devices. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229681000400302
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.